Brevan Howard Capital Management’s Dyne Therapeutics DYN Stock Holding History

Brevan Howard Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$675K	Sell	37,214 -120,755	-76%	-$2.08M	0.01%	1120
2025 Q4	$3.09M	Buy	157,969 +98,667	+166%	+$1.87M	0.03%	343
2025 Q3	$750K	Buy	59,302 +44,179	+292%	+$504K	﹤0.01%	1054
2025 Q2	$144K	Buy	+15,123	New	+$166K	﹤0.01%	1761
2025 Q1	–	Sell	-28,781	Closed	-$678K	–	1232
2024 Q4	$678K	Buy	+28,781	New	+$851K	﹤0.01%	530
2024 Q3	–	Sell	-10,053	Closed	-$355K	–	1211
2024 Q2	$355K	Buy	+10,053	New	+$292K	﹤0.01%	720

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Brevan Howard Capital Management's DYN Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Dyne Therapeutics (DYN) stake by 76% in Q1 2026, selling an estimated $2.08M and leaving 37,214 shares worth $675K. The position accounts for 0.01% of the portfolio, ranked #1120.

Brevan Howard Capital Management first reported a position in DYN in Q2 2024 and has held it in 6 quarters since. The position peaked at $3.09M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Brevan Howard Capital Management held 37,214 shares of Dyne Therapeutics worth $675K as of Q1 2026.
Brevan Howard Capital Management sold 120,755 Dyne Therapeutics shares in Q1 2026, an estimated $2.08M.
Dyne Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1120 holding.
Brevan Howard Capital Management first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Dyne Therapeutics position peaked at $3.09M in Q4 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.